Over the one-year period ending 30th June 2014, Telescan finalised its first phase strategic business plan for bringing its unique concept of preventative medicine based on scanning technologies to the global marketplace. This strategic plan effectively delivers prophylactic healthcare, which aims to help people live longer and healthier lives. The first step is to analyse the DNA of a person's genome in a search for biomarkers that are indicative of known risks that the individual has a genetic predisposition to one or more life threatening diseases during the course of their lifetime. This is followed up by second stage annual or semi annual MRI scans to check that none of the genetically identified risk factors are starting to materialise.
If early traces of disease start to present themselves at these scanning check-ups, this allows much earlier therapeutic intervention than would normally be possible. This in turn means that the patient has a much better chance of a successful outcome compared with a medical condition that is left to progress to the point where it manifests itself as major clinical symptoms. The earlier a disease is tackled using Telescan's prophylactic approach, the greater the probability of a cure.
There is a range of attractive multiple revenue streams that follow on from Telescan's twin track prophylactic scanning strategy.
In order to market this preventative medicine business model, Telescan has packaged its scanning strategies into a franchised format that the company is now seeking to roll-out on a global basis. Three franchise outlets have now been signed-up and these should start to deliver revenue during the next six months period commencing July 1st 2014. Further franchise outlets are currently under negotiation. The forthcoming six months will also see the Company commence an active marketing campaign.
Much of the expenses over the past year covered by this financial report, relate to legal, accounting and consultancy fees that are linked to the development of the Company's business model.
Majority of the Company shares have been sold at increasing premiums over their par value. Telescan plans to have all its initial authorised share capital of 100 000 Euros fully subscribed and paid in for by the end of September 2014. Following the completion of this stage, the Company then plans to build up its capital base by a further round of capital injection.
Michael Chambers
COO
Telescan AS
+44 79 6404 8080
mc@telescan.ee
